Laura P Stabile

List of Publications by Year
in descending order

43 papers	2,105 citations	257450 24 h-index	289244 40 g-index
43 all docs	43 docs citations	43 times ranked	2804 citing authors

#	Article	IF	Citations
1	Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy. International Journal of Molecular Sciences, 2022, 23, 81.	4.1	6
2	Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. Oncologist, 2022, 27, 839-848.	3.7	18
3	Syngeneic tobacco carcinogen–induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden. JCI Insight, 2021, 6, .	5.0	13
4	Estrogen Receptor ÃŸ in Cancer: To ÃŸ(e) or not to ÃŸ(e)?. Endocrinology, 2021, 162, .	2.8	8
5	Hormone gene signature guides a novel therapeutic opportunity to improve sensitivity to HER family inhibition in lung cancer. Translational Lung Cancer Research, 2020, 9, 1599-1605.	2.8	0
6	Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. Cancers, 2020, 12, 1537.	3.7	19
7	Interplay between estrogen and Stat3/NF-ÎºB-driven immunomodulation in lung cancer. Carcinogenesis, 2020, 41, 1529-1542.	2.8	9
8	Induction of Lung Tumors and Mutational Analysis in FVB/N Mice Treated with the Tobacco Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone. Methods in Molecular Biology, 2020, 2102, 149-160.	0.9	3
9	Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2020, 38, TPS6594-TPS6594.	1.6	0
10	When fat is favorable: the unexpected relationship between obesity and response to immunotherapy. Immunotherapy, 2020, 12, 1035-1039.	2.0	1
11	The estrogen pathway as a modulator of response to immunotherapy. Immunotherapy, 2019, 11, 1161-1176.	2.0	7
12	A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab. Biomarker Research, 2019, 7, 14.	6.8	6
13	Targeting the Temporal Dynamics of Hypoxia-Induced Tumor-Secreted Factors Halts Tumor Migration. Cancer Research, 2019, 79, 2962-2977.	0.9	16
14	Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 399-412.	1.1	25
15	Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nature Communications, 2018, 9, 4589.	12.8	57
16	Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer, 2018, 123, 91-98.	2.0	35
17	ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker. Journal of Cancer, 2018, 9, 2559-2570.	2.5	30
18	The Role of the Estrogen Pathway in the Tumor Microenvironment. International Journal of Molecular Sciences, 2018, 19, 611.	4.1	145

#	ARTICLE	IF	CITATIONS
19	Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer. Cancer, 2017, 123, 2936-2944.	4.1	36
20	The endocrine disrupting alkylphenols and 4,4′-DDT interfere with estrogen conversion and clearance by mouse liver cytosol. Reproductive Biology, 2017, 17, 185-192.	1.9	17
21	MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance. Molecular Oncology, 2017, 11, 628-639.	4.6	43
22	Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1443-1455.	5.6	31
23	Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates. Journal of Cancer, 2017, 8, 3916-3932.	2.5	3
24	Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer. Oncotarget, 2017, 8, 24063-24076.	1.8	26
25	ATM protein is deficient in over 40% of lung adenocarcinomas. Oncotarget, 2016, 7, 57714-57725.	1.8	35
26	Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome. Neoplasia, 2015, 17, 817-825.	5.3	29
27	Targeting the estrogen pathway for the treatment and prevention of lung cancer. Lung Cancer Management, 2014, 3, 43-52.	1.5	30
28	Co-targeting c-Met and COX-2 Leads to Enhanced Inhibition of Lung Tumorigenesis in a Murine Model with Heightened Airway HGF. Journal of Thoracic Oncology, 2014, 9, 1285-1293.	1.1	6
29	Estrogenic Steroid Hormones in Lung Cancer. Seminars in Oncology, 2014, 41, 5-16.	2.2	95
30	c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met. Clinical Cancer Research, 2013, 19, 380-392.	7.0	90
31	Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. Carcinogenesis, 2012, 33, 2181-2189.	2.8	48
32	HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF. Current Angiogenesis, 2012, 1, 52-63.	0.1	0
33	Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells. Clinical Cancer Research, 2011, 17, 4425-4438.	7.0	106
34	Combined Analysis of Estrogen Receptor β-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor Outcome. Clinical Cancer Research, 2011, 17, 154-164.	7.0	139
35	Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice. Cancers, 2010, 2, 2153-2170.	3.7	34
36	HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer. Clinical Cancer Research, 2009, 15, 3740-3750.	7.0	196

#	Article	IF	Citations
37	Estrogen receptor beta (ERβ2) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2009, 116, 102-109.	2.5	105
38	Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer, 2009, 64, 51-59.	2.0	82
39	Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Molecular Cancer Therapeutics, 2008, 7, 1913-1922.	4.1	37
40	Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis, 2005, 27, 1547-1555.	2.8	43
41	Estrogen receptor pathways in lung cancer. Current Oncology Reports, 2004, 6, 259-267.	4.0	93
42	Sex and gender differences in lung cancer. Journal of Gender-specific Medicine, 2003, 6, 37-48.	0.1	21
43	Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Research, 2002, 62, 2141-50.	0.9	362